Key Details
Annual ROE
-59.90%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Nov 02, 2023Recent annual earnings:
Mar 09, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
23 June '23 Baird
Outperform20 June '23 Wedbush
Neutral20 June '23 HC Wainwright & Co.
Neutral20 June '23 Baird
Neutral05 May '23 HC Wainwright & Co.
Buy04 May '23 Baird
Outperform10 Mar '23 Wedbush
Outperform10 Mar '23 HC Wainwright & Co.
Buy03 Nov '22 HC Wainwright & Co.
Buy03 Nov '22 Baird
OutperformScreeners with SURF included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Surface Oncology doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
Surface Oncology stock rallies on all-stock acquisition by Coherus
SURF
Market Watch16 June 2023
Surface Oncology Inc. SURF, +1.37% stock is up 49% in premarket trades on Friday after the cancer drug company agreed to be acquired by Coherus BioSciences Inc. CHRS, +0.56% in a stock-for-stock deal valued at up to $65 million. Coherus will issue shares of its common stock at a price of $5.2831 per share to acquire all outstanding shares of Surface stock for a total value equal to the sum of $40 million.
FAQ
- What is the primary business of Surface Oncology?
- What is the ticker symbol for Surface Oncology?
- Does Surface Oncology pay dividends?
- What sector is Surface Oncology in?
- What industry is Surface Oncology in?
- What country is Surface Oncology based in?
- When did Surface Oncology go public?
- Is Surface Oncology in the S&P 500?
- Is Surface Oncology in the NASDAQ 100?
- Is Surface Oncology in the Dow Jones?
- When was Surface Oncology's last earnings report?
- When does Surface Oncology report earnings?
- Should I buy Surface Oncology stock now?
What is the primary business of Surface Oncology?
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc.
What is the ticker symbol for Surface Oncology?
The ticker symbol for Surface Oncology is NASDAQ:SURF
Does Surface Oncology pay dividends?
No, Surface Oncology does not pay dividends
What sector is Surface Oncology in?
Surface Oncology is in the Healthcare sector
What industry is Surface Oncology in?
Surface Oncology is in the Biotechnology industry
What country is Surface Oncology based in?
Surface Oncology is headquartered in United States
When did Surface Oncology go public?
Surface Oncology's initial public offering (IPO) was on 19 April 2018
Is Surface Oncology in the S&P 500?
No, Surface Oncology is not included in the S&P 500 index
Is Surface Oncology in the NASDAQ 100?
No, Surface Oncology is not included in the NASDAQ 100 index
Is Surface Oncology in the Dow Jones?
No, Surface Oncology is not included in the Dow Jones index
When was Surface Oncology's last earnings report?
Surface Oncology's most recent earnings report was on 2 November 2023
When does Surface Oncology report earnings?
The date for Surface Oncology's next earnings report has not been announced yet
Should I buy Surface Oncology stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions